Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Twin Tree Management LP

Twin Tree Management LP lowered its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 39.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,431 shares of the biopharmaceutical company's stock after selling 29,820 shares during the quarter. Twin Tree Management LP's holdings in Royalty Pharma were worth $1,159,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Brooklyn Investment Group lifted its stake in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 876 shares during the period. Allworth Financial LP raised its holdings in Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares during the last quarter. Riverview Trust Co lifted its stake in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Remove Ads

Royalty Pharma Trading Up 0.6 %

Shares of RPRX stock traded up $0.20 on Friday, reaching $33.70. 7,065,345 shares of the stock were exchanged, compared to its average volume of 2,844,381. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market cap of $19.43 billion, a P/E ratio of 23.24, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The firm has a 50 day moving average of $32.25 and a two-hundred day moving average of $28.72. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, research analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.61%. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Royalty Pharma presently has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.